Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Partial Cystectomy

  • Author: E Jason Abel, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
 
Updated: Mar 26, 2014
 

Background

Definition

Partial or segmental cystectomy is a bladder-preserving treatment that involves full-thickness surgical removal of the bladder tumor and surrounding bladder wall.[1]

Key points

See the list below:

  • Only 5.8-18.9% of patients with muscle-invasive bladder cancer are suitable candidates for partial cystectomy.
  • Partial cystectomy is indicated in the patient with a normally functioning bladder with good capacity and a solitary tumor located where a 1-cm to 2-cm resection margin is possible.
  • For high-risk tumors, a multimodal approach with neoadjuvant or adjuvant chemotherapy and possible radiotherapy may be needed.
  • Absolute contraindications include carcinoma in situ (CIS) elsewhere in the bladder and multifocal tumors.
  • After surgery, ongoing surveillance, including imaging, cystoscopy, and cytology, is important because the local recurrence rate is high (37-78%).
  • Patients who have undergone partial cystectomy for bladder cancer should have cystoscopy and urinary cytologic examination every 3 months for at least 2 years. Regular CT scans of the pelvis and abdomen are recommended in the first several years of follow-up.
  • With proper patient selection, long-term, bladder-sparing survival rates with partial cystectomy range from 35-70%.

Partial cystectomy is used to treat both malignant and benign conditions of the bladder. Its primary malignant indication is for solitary, primary, muscle-invasive, or high-grade bladder cancer that does not involve specific regions of the bladder such as the bladder trigone, vesical neck, or posterior urethra and that can be resected with adequate surgical margins (1-2 cm). The classically described indication for partial cystectomy is for the removal of an adenocarcinoma or urachal carcinoma that develops in the dome of the bladder.

A better understanding of the natural history of urothelial carcinoma (transitional cell carcinoma) of the bladder has led to more stringent selection criteria for partial cystectomy; consequently, this procedure is being performed less frequently for malignant conditions (see Table 1). For example, the ideal clinical scenario would be if the bladder tumor was in an easily accessible location in the bladder, small in size (< 2cm) and no tumor(s) existed in the rest of the bladder. Partial cystectomy should only be considered if the cancer has not left its site of origin.

Despite advances in transurethral surgery for bladder tumors, some instances exist when the tumor cannot be completely resected and partial cystectomy is not only indicated but the most definitive procedure. For example, the morbidly obese patient with a superficial bladder tumor located in the upper aspect of the posterior bladder wall or dome might require a partial cystectomy because the surgeon was unable to reach the tumor transurethrally. Other indications for partial cystectomy include a need for adequate biopsy of radiation-induced ulcerations, the presence of a tumor in a bladder diverticulum, patient choice, palliation of severe local symptoms, preservation of native bladder function and continence, and poor surgical risk for more aggressive procedures such as radical cystectomy.

A few benign conditions of the bladder can be managed with partial cystectomy. These include resection of bladder diverticula, colovesical fistula repair, vesicovaginal fistula repair and less commonly for cavernous hemangiomas, ulcerative interstitial cystitis, and localized endometriosis of the bladder.

Partial cystectomy has certain advantages over radical cystectomy, such as preserving a functionally continent native urinary reservoir and sparing potency in males. In addition, because a separate urinary diversion procedure (as is necessary in radical cystectomy) is not performed, some surgeons view partial cystectomy as a less morbid operation, suited for high-risk patients and palliative situations. The main disadvantage of partial cystectomy lies in the historically high local recurrence rates of bladder cancer, with only part of a globally diseased urothelium addressed. Although partial cystectomy plays a limited role in the treatment of bladder cancer, in properly selected patients, similar oncologic results can be achieved as seen in patients treated with radical cystectomy. This review focuses on the current applications and indications for partial cystectomy, with an emphasis on the treatment of bladder cancer.

Next

History of the Procedure

Historically, this operation has been performed since the 19th century, when it was thought that many patients with bladder cancer would be ideal candidates. Little was known about how bladder cancer may affect the entire bladder despite the appearance of a solitary tumor. The widespread use of this operation in the mid-1950s led to high local recurrence rates from 37% to 78%.[2, 3] The advent and technical improvements of transurethral resection (TUR) have made it possible to initially resect most bladder tumors.

Table 1. Proportion of Patients With Bladder Cancer Treated With Partial Cystectomy (Open Table in a new window)

Source Total Patients With Bladder Cancer Patients Treated With Partial Cystectomy (%)
Utz et al (1973) 3454 199 (5.8)
Brannan et al (1978) 551 49 (7.1)
Faysal and Freiha (1979) 859 117 (13.6)
Merrell et al (1979) 585 54 (9.2)
Ojeda and Johnson (1983) 397 23 (5.8)
Jardin and Vallencien (1984) 475 90 (18.9)
Hayter et al (2000) 20,822 729 (3.5)
Holzbeierlein et al (2004) 935 58 (6.2)
Previous
Next

Epidemiology

Frequency

Bladder cancer is the sixth most common type of cancer diagnosed in the United States, representing 4.4% of all new cancer cases. Based on the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, an estimated 72,570 new cases of bladder cancer were diagnosed in 2013 and 15,210 persons were estimated to die from the disease.

Currently, the overall male-to-female patient ratio is approximately 4:1.

The ratio of bladder cancer in white Americans compared with African Americans is 1.5-2.1:1.

The median age of patients is 73 years at time of diagnosis, with incidence and mortality per pathologic grade increasing as a function of age.

Since 1950, the incidence of bladder cancer has increased by 50%, but the overall mortality rate (primarily in men) has decreased by 33%. More than 560,000 people in the United States are currently living with bladder cancer.

Previous
Next

Etiology

The etiology of bladder cancer, a frequent indication for bladder resection, is unknown. Postulated theories include environmental carcinogens (eg, chemicals, ultraviolet light, radiation), aberration of normal cell growth regulation (eg, oncogene induction, suppressor gene negation), and abnormalities in the genetic composition of malignant cells.

Chemical exposures that may increase the risk of bladder cancer include aromatic amines, dietary nitrites, and nitrates. These include aniline dyes (eg, 2-naphthylamine, 4-aminobiphenyl, 4-nitrobiphenyl, 4-4-diaminobiphenyl [benzidine], 2-amino-1-naphthol), combustion gases, coal soot, chlorinated aliphatic hydrocarbons, and acrolein dyes. Smoking is associated with an up to 4-fold increase in the risk of bladder cancer. Other implicated factors include coffee and tea, phenacetin (an analgesic), chronic cystitis, the presence of chronic indwelling catheters, bladder calculi, pelvic irradiation, and exposure to cyclophosphamide. Schistosomiasis of the urinary bladder is associated with a higher incidence of squamous cell carcinoma. Currently, no evidence links bladder cancer to heredity.

Recent investigations have addressed the arsenic content of drinking water. International studies in Taiwan, Chile, and Argentina have suggested that as little as 10.1 mcg/L of arsenic in drinking water increases the risk.[4, 5] In Taiwan, population studies of 8102 residents found that concentrations of 10-50, 50-100, and more than 100 mcg/L of arsenic in drinking water (compared with levels < 10 mcg/L) increase the relative risk of developing transitional cell carcinoma to 1.9, 8.2, and 15.3, respectively.[4] In Chile, studies of arsenic levels from 100-570 mcg/L revealed an elevated standardized mortality ratio of bladder cancer of 6 in men and 8.2 in women.[5] In the United States, it is estimated that 350,000 persons are exposed to arsenic levels of more than 50 mcg/L and that 2.5 million are exposed to levels higher than 25 mcg/L. In one study, the relative risk estimate for an average level of arsenic in US drinking water was 1 in 1000 persons.[6]

Oncogenes and tumor suppressor genes implicated in bladder cancer include TP53, retinoblastoma gene (Rb), p15, and p16. Alterations in TP53, a normal tumor suppressor gene found on chromosome 17p which controls apoptosis, lead to more aggressive bladder cancers. Ongoing studies are exploring the clinical implications of these tumor suppressor genes. Currently, conventional staging and grading are sufficient.

The tumor suppressor gene, Rb, is found on chromosome 13q. A mutated Rb gene or phosphorylated Rb gene leads to dissociation of its product protein, pRB, from the normally complexed transcription factor, E2F. Dissociated E2F drives the transition from G1 to S phase in cellular mitosis.

Two more protein regulators encoded on chromosome 9p, p15 and p16, inhibit nuclear cyclin-dependent kinases from phosphorylating pRB. When p15 and p16 mutate, they can no longer prevent phosphorylation of pRB, resulting in dissociation of the pRB-E2F complex, and free E2F is allowed to stimulate the cell's G1- to S-phase proliferation. Very aggressive high-grade bladder tumors have been associated with alterations in TP53. Mutations in Rb, p15, and p16 have been associated with low-grade superficial tumors.

Bladder cancer often behaves as a field disease; the entire urothelium, from the renal pelvis to the urethra, is susceptible to malignant transformation. Urothelial carcinoma cells may also have the ability to migrate and implant at different sites along the urothelium.

Previous
Next

Presentation

A thorough history should be obtained, and a thorough physical examination should be performed. In patients with bladder cancer, the most common presenting symptom is painless hematuria (85%). Hematuria is often intermittent; therefore, a single urinalysis finding may not be significant. Bladder irritability that manifests as urinary frequency, urgency, and dysuria is the second most common symptom. These symptoms rarely occur without hematuria (microscopic or gross). Flank pain due to ureteral obstruction, lower-extremity edema, and pelvic masses are other presenting symptoms. Symptoms of advanced disease, such as weight loss and abdominal or bone pain, are rare because patients usually seek medical attention before these develop.

Previous
Next

Indications

Indications for partial cystectomy in malignancy

Urothelial carcinoma (also called transitional cell carcinoma) accounts for the vast majority of bladder cancer in the United States. However, in some countries, squamous cell carcinoma is the dominant subtype of bladder cancer because of chronic infection with Schistosomiasis hematobium.

Partial cystectomy for urothelial carcinoma is recommended in properly selected cases. Suggested selection criteria include the following:

  • No history of multifocal bladder cancer (negative random bladder biopsies)
  • No evidence of metastatic disease
  • Absence of multiple lesions (including carcinoma in situ)
  • Solitary, high grade muscle-invasive tumor located in a position that is amenable to wide resection (ideally achieving 1-2 cm margins)
  • Tumor located away from the ureteral orifices (although resection and re-implantation is possible, but associated with poorer prognosis) and not involving bladder neck or prostate
  • Expectation that the residual postoperative bladder will have adequate capacity and compliance to ensure functionality

As a result of such strict criteria, relatively few patients with muscle invasive bladder cancer are candidates for bladder-sparing surgery.[7] The most common lesions amenable to partial cystectomy are high-grade tumors located in the lateral walls or dome of the bladder.

Cancer in bladder diverticula

Diverticular cancers comprise 1.5-10% of all bladder cancers and are more likely to penetrate the bladder wall because of the relatively thin nature of the wall and its lack of thick muscular layers. Transurethral resection of the tumor may be an option; however, inadvertent perforation is possible because of the paucity of muscle fibers in the diverticulum, which may lead to dissemination of urothelial cancer cells. Urothelial carcinoma in a bladder diverticulum is a common reason for performing partial cystectomy. Historical series suggested a high rate of recurrence and poor prognosis for diverticular tumors, but more contemporary data suggest that complete tumor resection with partial cystectomy results in 5-year disease-specific survival rates of around 70%.[8]

Partial cystectomy for cancers other than urothelial carcinoma

Squamous cell carcinoma has a poor prognosis and is not responsive to chemotherapy and radiation. Although some series describe the feasibility of partial cystectomy, this approach has not been studied extensively because of its low prevalence in the western world (3-7% in the United States).[9] In contrast, 75% of all bladder cancers in Egypt are of squamous cell derivation because of S. hematobium infection. In some reports, bilharzial bladder cancer (bladder cancer associated with Schistosomiasis) has a similar prognosis to transitional cell cancer when compared stage-for-stage, but whether this is true for nonbilharzial squamous cell carcinoma is unclear.

Primary adenocarcinoma of the bladder may be treated with partial cystectomy in select cases. Urachal lesions, which represent 20-40% of all primary bladder adenocarcinomas, are thought to arise from residual transitional cells that line the urachal remnant in the dome of the bladder. Historically, the overall, 5-year survival rate associated with urachal adenocarcinoma has been poor (6-15%).

However, recent evidence has shown that extended partial cystectomy with removal of the bladder segment, posterior rectus fascia, peritoneum, and umbilicus offers the best chance for survival. In a study by Dandekar et al, the 5-year survival rate after partial cystectomy for urachal adenocarcinoma was 56.3%.[10] Herr found that contained urachal adenocarcinomas that were completely resected using extended partial cystectomy had a favorable disease-free rate (77%).[11] Following partial cystectomy, cure rates of well-differentiated urachal adenocarcinomas have been reported to approach 100%.

Rhabdomyosarcomas of the bladder comprise 17-50% of all genitourinary rhabdomyosarcomas. These patients have also been successfully treated with partial cystectomy as an alternative to radical cystectomy or chemotherapy. Disease-free survival rates have been reported as high as 78.5% with 2- to 16-year follow-up after partial cystectomy with or without neoadjuvant chemotherapy and radiation. Most of these patients were able to retain functional bladders with minimal lower urinary tract symptoms.[12]

Pheochromocytoma of the bladder is a rare neoplasm, accounting for less than 1% of all bladder tumors. Pheochromocytoma is a tumor of neuroendocrine origin that tends to be functional. Typical presenting symptoms include hematuria and symptoms related to catecholamine secretion, including paroxysmal hypertension and micturition-related headache, palpitations, and syncope. In a recent systematic review, Beilan et al reported that partial cystectomy was the primary treatment for approximately 70% of these tumors, with good symptomatic control and low morbidity. Irrespective of treatment, at a mean follow-up of 35 months, 14.2% had disease recurrence, 9.4% had metastasis, and 56.6% had no evidence of disease. Of note, surgical treatment (whether partial or radical cystectomy) is rarely curative if the disease is metastatic.[13]

Though primarily described in case reports, partial cystectomy has also been used in the treatment of bladder leiomyosarcoma, a rare but aggressive tumor. As with most patients undergoing partal cystectomy, these patients must be followed closely for recurrence or metastasis.[14]

Rectal, colon, prostate, uterus, cervix, or ovarian cancers that are locally advanced can be treated with partial cystectomy in selected cases, although pelvic exenteration may be required. A local recurrence rate of 17% and a 3-year survival rate of 39-74% has been reported with negative surgical margins.[15, 16]

Benign conditions

Nonmalignant conditions of the bladder can also be managed with partial cystectomy. These conditions include bladder diverticula, cystic hydatid disease, cavernous hemangiomas, paraganglioma, leiomyomas, refractory interstitial cystitis, colovesical fistula, vesicovaginal fistula and endometriosis of the bladder.[17, 18]

Previous
Next

Relevant Anatomy

The adult bladder is located in the anterior pelvis and is enveloped by extraperitoneal fat and connective tissue. It is separated from the pubic symphysis by an anterior prevesical space known as the retropubic space (of Retzius). The dome of the bladder is covered by peritoneum, and the bladder neck is fixed to neighboring structures by reflections of the pelvic fascia and by true ligaments of the pelvis.

The body of the bladder receives support from the external urethral sphincter muscle and the perineal membrane inferiorly and the obturator internus muscles laterally (see the image below).

Gross anatomy of the bladder. Gross anatomy of the bladder.

For more information about the relevant anatomy, see Bladder Anatomy. See also Female Urethra Anatomy, Female Urinary Organ Anatomy, Male Urethra Anatomy, and Male Urinary Organ Anatomy.

Previous
Next

Contraindications

In patients with bladder cancer being considered for partial cystectomy, the entire urothelial tract from the kidneys to the urethra must be evaluated thoroughly. Prior to surgery, no other malignant disease should be anywhere in the urinary tract. The presence of multifocal disease or CIS is considered an absolute contraindication to partial cystectomy.

Other contraindications to partial cystectomy include the following:

  • Cellular atypia in random biopsy specimens
  • Prostatic invasion
  • Bladder neck or trigonal invasion
  • Presence of lymphovascular invasion in biopsy specimen
  • Inability to achieve adequate surgical margins
  • Prior radiation therapy
  • Inadequate bladder volume following resection
  • Evidence of metastatic disease
  • Poor preoperative performance status conveying high surgical risk
Previous
 
 
Contributor Information and Disclosures
Author

E Jason Abel, MD Assistant Professor of Urologic Oncology, Department of Urology, University of Wisconsin Hospital and Clinics, University of Wisconsin School of Medicine and Public Health; Attending Urologist, William S Middleton Memorial Veterans Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Tracy Downs, MD Associate Professor of Urology, University of Wisconsin School of Medicine and Public Health

Tracy Downs, MD is a member of the following medical societies: American College of Surgeons, American Urological Association, Society of Urologic Oncology

Disclosure: Nothing to disclose.

Aaron M Potretzke, MD Resident Physician, Department of Urology, University of Wisconsin Hospital and Clinics

Aaron M Potretzke, MD is a member of the following medical societies: American Medical Association, Minnesota Medical Association

Disclosure: Nothing to disclose.

Kelvin Wong, MD Resident Physician, Department of Urology, University of Wisconsin Hospital and Clinics

Kelvin Wong, MD is a member of the following medical societies: American College of Surgeons, American Medical Association

Disclosure: Nothing to disclose.

Jennifer E Heckman, MD, MPH Resident Physician, Department of Urology, University of Wisconsin Hospital and Clinics

Jennifer E Heckman, MD, MPH is a member of the following medical societies: American Urological Association, Endourological Society, Society of Women in Urology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Bradley Fields Schwartz, DO, FACS Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine

Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, Society of Laparoendoscopic Surgeons, Society of University Urologists, Association of Military Osteopathic Physicians and Surgeons, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Additional Contributors

Gamal Mostafa Ghoniem, MD, FACS Professor and Vice Chair of Urology, Chief, Division of Female Urology, Pelvic Reconstructive Surgery, and Voiding Dysfunction, Department of Urology, University of California, Irvine, School of Medicine

Gamal Mostafa Ghoniem, MD, FACS is a member of the following medical societies: American Urogynecologic Society, International Continence Society, International Urogynaecology Association, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, American College of Surgeons, American Urological Association

Disclosure: Received honoraria from Astellas for speaking and teaching; Received grant/research funds from Uroplasty for none; Partner received honoraria from Allergan for speaking and teaching.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Martin I Resnick, MD; Jason T Jankowski, MD; Edward E Cherullo, MD; Matthew L Steinway, MD; and Adrian H Feng, MD, to the development and writing of this article.

References
  1. Nieh PT and Marshall FF. Surgery of Bladder Cancer. Campbell-Walsh Urology. ninth. 2007. 2503-2505.

  2. Lindahl F, Jørgensen D, Egvad K. Partial cystectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol. 1984. 18(2):125-9. [Medline].

  3. Given RW, Wajsman Z:. Bladder sparing treatments for muscle-invasive transitional cell carcinoma of the bladder. AUA Update Series. 1997. 16:41-48.

  4. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol. 2001 Mar 1. 153(5):411-8. [Medline].

  5. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol. 1998 Apr 1. 147(7):660-9. [Medline].

  6. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, et al. Cancer risks from arsenic in drinking water. Environ Health Perspect. 1992 Jul. 97:259-67. [Medline].

  7. Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am. 1992 Nov. 19(4):701-11. [Medline].

  8. Golijanin D, Yossepowitch O, Beck SD, Sogani P, Dalbagni G. Carcinoma in a bladder diverticulum: presentation and treatment outcome. J Urol. 2003 Nov. 170(5):1761-4. [Medline].

  9. Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol. 2000 Jan. 37(1):85-9. [Medline].

  10. Dandekar NP, Dalal AV, Tongaonkar HB, Kamat MR. Adenocarcinoma of bladder. Eur J Surg Oncol. 1997 Apr. 23(2):157-60. [Medline].

  11. Herr HW. Urachal carcinoma: the case for extended partial cystectomy. J Urol. 1994 Feb. 151(2):365-6. [Medline].

  12. Hays DM, Raney RB, Wharam MD, Wiener E, Lobe TE, Andrassy RJ, et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with or without radiotherapy. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee. J Pediatr Hematol Oncol. 1995 Feb. 17(1):46-52. [Medline].

  13. Beilan J, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol. 2013 Apr 29. 13(1):22. [Medline].

  14. Xu YF, Wang GC, Zheng JH, Peng B. Partial cystectomy: Is it a reliable option for the treatment of bladder leiomyosarcoma?. Can Urol Assoc J. 2011 Feb. 5(1):E11-3. [Medline].

  15. Balbay MD, Slaton JW, Trane N, Skibber J, Dinney CP. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer. 1999 Dec 1. 86(11):2212-6. [Medline].

  16. Nyam DC, Seow-Choen F, Ho MS, Goh HS. Bladder involvement in patients with colorectal carcinoma. Singapore Med J. 1995 Oct. 36(5):525-6. [Medline].

  17. Tai HC, Chung SD, Wang SM, Chueh SC, Yu HJ. Laparoscopic partial cystectomy for various bladder pathologies. BJU Int. 2007 Aug. 100(2):382-5. [Medline].

  18. Ikeda M, Endo F, Shiga Y, Oguchi T, Yashi M, Hattori K. [Cystoscopy-assisted partial cystectomy for paraganglioma of the urinary bladder]. Hinyokika Kiyo. 2008 Sep. 54(9):611-4. [Medline].

  19. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008 Jun. 2(3):212-21. [Medline].

  20. Shirodkar SP, Lokeshwar VB. Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?. Expert Rev Anticancer Ther. 2008 Jul. 8(7):1111-23. [Medline].

  21. Wang LJ, Wong YC, Huang CC, Wu CH, Hung SC, Chen HW. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol. 2010 Jan. 183(1):48-55. [Medline].

  22. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec. 22(12):1435-48. [Medline].

  23. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011 Jan. 185(1):72-8. [Medline].

  24. Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000 Sep. 164(3 Pt 1):627-32. [Medline].

  25. Herr HW. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009 Apr. 55(4):920-1. [Medline].

  26. Dorin RP, Skinner EC. Extended lymphadenectomy in bladder cancer. Curr Opin Urol. 2010 Sep. 20(5):414-20. [Medline].

  27. Colombo JR Jr, Desai M, Canes D, Frota R, Haber GP, Moinzadeh A, et al. Laparoscopic partial cystectomy for urachal and bladder cancer. Clinics. December 2008. 63:731-4. [Medline].

  28. Tareen BU, Mufarrij PW, Godoy G, Stifelman MD. Robot-assisted laparoscopic partial cystectomy and diverticulectomy: initial experience of four cases. J Endourol. 2008 Jul. 22(7):1497-500. [Medline].

  29. Spiess PE, Correa JJ. Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol. 2009 Sep-Oct. 35(5):609. [Medline].

  30. Allaparthi S, Ramanathan R, Balaji KC. Robotic partial cystectomy for bladder cancer: a single-institutional pilot study. J Endourol. 2010 Feb. 24(2):223-7. [Medline].

  31. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, et al. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. Urol Oncol. 2014 Jan. 32(1):53.e9-14. [Medline].

  32. Peress JA, Waterhouse K, Cole AT. Complications of partial cystectomy in patients with high grade bladder carcinoma. J Urol. 1977 Nov. 118(5):761. [Medline].

  33. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. September 2008. 72:613-6. [Medline].

  34. Resnick MI, O'Conor VJ Jr. Segmental resection for carcinoma of the bladder: review of 102 patients. J Urol. 1973 Jun. 109(6):1007-10. [Medline].

  35. Faysal MH, Freiha FS. Evaluation of partial cystectomy for carcinoma of bladder. Urology. 1979 Oct. 14(4):352-6. [Medline].

  36. Bruins HM, Wopat R, Mitra AP, Cai J, Miranda G, Skinner EC, et al. Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. BJU Int. 2013 Mar. 111(3 Pt B):E37-42. [Medline].

  37. Fahmy N, Aprikian A, Tanguay S, Mahmud SM, Al-Otaibi M, Jeyaganth S. Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol. 2010 Aug. 28(4):419-23. [Medline].

  38. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun. 175(6):2058-62. [Medline].

  39. Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF, et al. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol. 2012 Oct. 188(4):1115-9. [Medline].

  40. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28. 349(9):859-66. [Medline].

  41. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001 Oct 15. 19(20):4005-13. [Medline].

  42. Chung SD, Tai HC, Chueh SC. Laparoscopic partial cystectomy for a vesical leiomyoma. Int Urogynecol J Pelvic Floor Dysfunct. May 2007. 18:565-6. [Medline].

  43. Chung SD, Tai HC, Chueh SC. Laparoscopic partial cystectomy for a vesical leiomyoma. Int Urogynecol J Pelvic Floor Dysfunct. 2007 May. 18(5):565-6. [Medline].

  44. Duncan RE, Bennett DW, Evans AT, Aron BS, Schellhas HF. Radiation-induced bladder tumors. J Urol. 1977 Jul. 118(1 Pt 1):43-5. [Medline].

  45. Greene FL. Urinary Bladder. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002. 335-40.

  46. Herr HW. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol. 2009 Apr. 55(4):920-1. [Medline].

  47. Hinman F. Atlas of Urologic Surgery. 2nd ed. Philadelphia, Pa: WB Saunders; 1998. 500-4.

  48. Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol. 2004 Sep. 172(3):878-81. [Medline].

  49. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2010/.

  50. Ikeda M, Endo F, Shiga Y, Oguchi T, Yashi M, Hattori K, et al. Cystoscopy-assisted partial cystectomy for paraganglioma of the urinary bladder. Hinyokika Kiyo. September 2008. 54:611-4. [Medline].

  51. Inoue T, Kinoshita H, Satou M, Oguchi N, Kawa G, Muguruma K, et al. Complications of urologic laparoscopic surgery: a single institute experience of 1017 procedures. J Endourol. 2010 Feb. 24(2):253-60. [Medline].

  52. Jardin A, Vallencien G. Partial cystectomy for bladder tumors. Kuss R, Khoury S, Denis LJ, et al, eds. Bladder cancer, Part A: Pathology, Diagnosis and Surgery. New York, NY: AR Liss; 1984. 375.

  53. Lang EK, Thomas R, Davis R, Myers L, Sabel A, Macchia R, et al. Multiphasic helical computerized tomography for the assessment of microscopic hematuria: a prospective study. J Urol. 2004 Jan. 171(1):237-43. [Medline].

  54. Messing EM, Catalona W. Urothelial tumors of the urinary tract. Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. 7th ed. Philadelphia, Pa: WB Saunders; 1998. 2329-71.

  55. Soloway MS. Commentary. Hinman F, ed. Atlas of Urologic Surgery. Atlas of Urologic Surgery. 2nd ed. Philadelphia: WB Saunders Co; 1998. 504.

  56. Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 2010 Aug. 184(2):475-80. [Medline].

  57. Tai HC, Chung SD, Wang SM, Chueh SC, Yu HJ. Laparoscopic partial cystectomy for various bladder pathologies. BJU Int. December 2007. 100:382-5. [Medline].

 
Previous
Next
 
Papillary bladder tumors such as this one are typically of low stage and grade (Ta-G1). Courtesy of Abbott and Vysis Inc.
Gross anatomy of the bladder.
Table 1. Proportion of Patients With Bladder Cancer Treated With Partial Cystectomy
Source Total Patients With Bladder Cancer Patients Treated With Partial Cystectomy (%)
Utz et al (1973) 3454 199 (5.8)
Brannan et al (1978) 551 49 (7.1)
Faysal and Freiha (1979) 859 117 (13.6)
Merrell et al (1979) 585 54 (9.2)
Ojeda and Johnson (1983) 397 23 (5.8)
Jardin and Vallencien (1984) 475 90 (18.9)
Hayter et al (2000) 20,822 729 (3.5)
Holzbeierlein et al (2004) 935 58 (6.2)
Table 2. Options Other than Partial Cystectomy
Study Number of Patients Induction Therapy % Complete Response Consolidation Therapy % Overall Survival (years) % Overall Survival with Bladder Intact (years)
Housset et al 120 Bifractionated XRT + concurrent cisplatin + 5-fluorouracil 77 Bifractionated XRT + concurrent 5-fluorouracil + cisplatin 63 (5)  



...



Sauer et al 184 45-54 Gy XRT + concurrent cisplatin or carboplatin 80 None 56 (5) 41 (5)
Fellin et al 56 2 cycles MCVa, 40 Gy XRT + concurrent cisplatin 50 24 Gy XRT + concurrent cisplatin 55 (5) 41 (5)
Tester et al 49 40 Gy XRT + concurrent cisplatin 66 24 Gy XRT + concurrent cisplatin 60 (4) 42 (4)
Tester et al 91 2 cycles MCV, 39.6 Gy XRT + concurrent cisplatin 75 25.2 Gy XRT + concurrent cisplatin 62 (4) 44 (4)
Shipley et al 61 2 cycles MCVa, 39.6 Gy XRT + concurrent cisplatin 61 25.2 Gy XRT + concurrent cisplatin 48 (5) 36 (5)
Shipley et al 62 39.6 Gy XRT + concurrent cisplatin 55 25.2 Gy XRT + concurrent cisplatin 49 (5) 40 (5)
Kachnic et al 106 2 cycles MCV, 40 Gy XRT + concurrent cisplatin 66 24.8 Gy XRT + concurrent cisplatin 52 (5) 43 (5)
Zietman et al 18 Bifractionated XRT + concurrent cisplatin + 5-fluorouracil 78 Bifractionated XRT + concurrent cisplatin + 5-fluorouracil + 3 cycles MCV 83 (3) 78 (3)
Table 3. Various Studies and Their Corresponding Recurrence Rates
Studies Recurrence rates
Resnick and O'Connor (1973) 76%
Evans and Texter (1975) 40%
Novick and Stewart (1976) 50%
Peress et al (1977) 54%
Cummings et al (1978) 49%
Schoborg et al (1979) 70%
Faysal and Freiha (1979) 78%
Jardin and Vallencien (1984) 78%
Lindahl et al (1984) 58%
Kaneti (1986) 38%
Dandekar et al (1995) 43%
Holzbeierlein et al (2004) 19%
Kassouf et al (2006) 49%
Knoedler et al (2012) 43%
Table 4. Survival Rates by Tumor Grade
Source Five-year Survival (%) Ten-year Survival (%)
Grade I Grade II Grade III/IV Grade I Grade II Grade III/IV
Magri (1962)  



88



33 34 - - -
Utz et al (1973) 100 48 39 - - -
Novick and Stewart (1976) 100 75 40 0 67 8
Brannan et al (1978) 50 62 55 50 33 30
Cummings et al (1978) 100 96 32 - - -
Schoborg et al (1979) 75 62 26 50 28 4
Faysal and Freiha (1979) 100 53 30 25 20 8
Merrell et al (1979) 78 56 22 83 32 0
Kaneti (1986) 75 46 46 - - -
Dandekar et al (1995) 100 94.4 53.5 - - -
Table 5. Survival Rates by Tumor Stage
Source Five-year Survival (%) Ten-year Survival (%)
T0 T1 T2 T3 T4 Overall T0 T1 T2 T3 T4 Overall
Magri (1962) - 80 38 26 0 42 - - - - - -
Long et al (1962) 80 67 43 9 0 - - - - - - -
Cox et al (1969) - - 20 16 - - - - - - - -
Resnick and O'Connor (1978) 75 71 77 12.5 20 35 - - - - - -
Utz et al (1973) - 68 47 29 0 39 - - - - - -
Evans and Texter (1975) - 69 43 14 0 0 - - - - - 21
Novick and Stewart (1976) - 67 53 20 - 46 - 67 44 - - 36
Brannan et al (1978) 100 69 54 33 0 57 - 31 36 11 - 32
Cummings et al (1978) - 79 80 6 - 60 - - - - - -
Schoborg et al (1979) 69 69 29 12 100 43 - 37 0 0 0 12
Faysal and Freiha (1979) 75 58 29 7 0 40 21 15 13 7 0 9
Merrell et al (1979) 100 100 67 25 - 48 - 100 33 0 0 32
Lindahl et al (1984) - 59 38 - - 42 - 48 25 - 0 38
Kaneti (1986) - 68 40 33 0 48 - - - - - -
Smaldone et al (2008) - - - - - 70            
a Stage T3a/T3b
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.